Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Nasus Pharma Ltd. (NYSE: NSRX) announced the appointment of Brendan P. O'Grady as Chief Executive Officer, effective July 27, 2026. O'Grady, a pharmaceutical industry veteran with 35 years of experience and former CEO of Teva USA, will lead the company's growth strategy with focus on commercializing NS002, an intranasal epinephrine treatment for anaphylaxis targeting a $2 billion market opportunity. He succeeds Dan Teleman in the leadership transition.
07/28/2026, 7:30 AM • GlobeNewswire
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
Virtual Investor Conferences announced that presentations from the June 24-25 Life Sciences Virtual Investor Forum are now available for on-demand viewing for 90 days. Twenty companies across the life sciences sector presented at the forum, with select companies still accepting 1x1 management meeting requests through June 19th.
06/26/2026, 8:35 AM • GlobeNewswire
Nasus Pharma reported positive Phase 2 results for NS002, its intranasal epinephrine powder, demonstrating statistically significant improvements in absorption speed compared to EpiPen®. The company plans to initiate a pivotal study in Q4 2026 and is advancing pipeline candidates NS003, NS004, and NS005 toward first-in-human studies in H2 2026. With $4.3 million in cash as of December 31, 2025, plus a $15 million private placement closed in February 2026, the company is well-funded through Q2 2027.
03/25/2026, 9:00 AM • GlobeNewswire
Nasus Pharma to Participate in Upcoming Investor Conferences
Nasus Pharma Ltd. (NYSE: NSRX), a clinical-stage pharmaceutical company developing intranasal products, announced that CEO Dan Teleman will present at three upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference (Feb 25), BIO Investment & Growth Summit (Mar 2), and Citizens Life Sciences Conference (Mar 3). The company is focused on developing NS002, an intranasal powder Epinephrine product as a needle-free alternative to autoinjectors for anaphylaxis treatment.
02/20/2026, 8:00 AM • GlobeNewswire
Nasus Pharma Announces Closing of $15.0 Million Private Placement
Nasus Pharma Ltd. (NYSE: NSRX) announced the closing of a private placement raising approximately $15.0 million gross proceeds through the sale of 2,695,425 ordinary shares and accompanying warrants at $5.565 per share. The company plans to use the proceeds to advance its NS002 intranasal epinephrine powder product candidate toward a pivotal study and NDA submission, while expanding its pipeline of intranasal powder-based programs.
02/13/2026, 8:00 AM • GlobeNewswire
Nasus Pharma Announces Pricing of $15.0 Million Private Placement
Nasus Pharma Ltd. (NYSE: NSRX), a clinical-stage pharmaceutical company, announced a private placement of 2.7 million ordinary shares and warrants for approximately $15 million in gross proceeds. The funds will be used to advance pivotal clinical development of NS002, an intranasal epinephrine product for anaphylaxis treatment, and to initiate first-in-human studies for other pipeline products.
02/10/2026, 11:03 PM • GlobeNewswire
Nasus Pharma reported positive interim Phase 2 results for NS002, its intranasal epinephrine powder for anaphylaxis treatment. The drug demonstrated faster absorption and higher peak epinephrine levels compared to EpiPen, with 91% of participants reaching therapeutic levels at 5 minutes versus 67% with EpiPen. NS002 was well-tolerated with no serious adverse events. Full Phase 2 results are expected by Q1 2026, with pivotal study initiation planned for Q4 2026.
01/20/2026, 8:00 AM • GlobeNewswire
Nasus Pharma Announces Closing of Initial Public Offering
Nasus Pharma completed its initial public offering, raising $10 million by selling 1,250,000 ordinary shares at $8.00 per share. The company plans to use proceeds to develop its intranasal Epinephrine program and for general corporate purposes.
08/14/2025, 4:05 PM • Benzinga
